Table 1. Clinical and procedural characteristics of all STEMI patients.
| Variables | Value |
| Age (years) | 57.6 ± 12.6 |
| Female gender, n (%) | 45 (25.8) |
| LVEF (%) | 43.7 ± 7.7 |
| MI region | |
| Anterior MI, n (%) | 54 (31.0) |
| Septal MI, n (%) | 27 (15.5) |
| Lateral MI, n (%) | 23 (13.2) |
| Inferior MI, n (%) | 48 (27.5) |
| Posterior MI, n (%) | 18 (10.3) |
| Right ventricle MI, n (%) | 4 (2.2) |
| KILLIP class, n (%) | |
| I | 72 (41.3) |
| II | 53 (30.4) |
| III | 20 (11.4) |
| IV | 29 (16.6) |
| Drug usage, n (%) | |
| Beta-blockers | 40 (22.9) |
| Calcium channel blockers | 28 (16.0) |
| ACEIs/ARBs | 58 (33.3) |
| ASA | 16 (9.1) |
| Clopidogrel/prasugrel/ticagrelor | 9 (5.1) |
| Warfarin/NOACs | 6 (3.4) |
| Statins | 23 (13.2) |
| Co-medication for MI, n (%) | |
| Dual antiplatelet therapy, n(%) | |
| ASA plus clopidogrel | 130 (74.7) |
| ASA plus ticagrelor | 35 (20.1) |
| ASA plus prasugrel | 9 (5.1) |
| Glycoprotein IIb/IIIa inhibitors (tirofiban) | 60 (34.4) |
| Thrombus aspiration | 23 (13.2) |
| Intra-aortic balloon pumping | 7 (4.0) |
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ASA, acetylsalicylic acid; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NOACs, novel oral anticoagulant drugs; STEMI, ST-segment elevation myocardial infarction.